Skip to main content
Elsevier
View Cart

New Antibody Formats

  • 1st Edition, Volume 369 - June 20, 2022
  • Latest edition
  • Editors: Fernando Aranda Vega, Pedro Berraondo, Lorenzo Galluzzi
  • Language: English

New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting intere… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting interesting chapters on a variety of important topics, including Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.

Key features

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in the International Review of Cell and Molecular Biology serials
  • Updated release includes the latest information on New Antibody Formats

Readership

Academics, researchers and educators

Table of contents

1. Current innovative engineered antibodies
Jose Yelamos

2. Opportunities and challenges of bi-specific antibodies
Aina Segués, Shuyu Huang, Alice Sijts, Pedro Berraondo and Dietmar M. Zaiss

3. Applications of trimerbodies in cancer immunotherapy
Marta Compte, Laura Sanz and Luis Álvarez-Vallina

4. Anticalin®-based therapeutics: Expanding new frontiers in drug development
Aizea Morales-Kastresana, Martin Siegemund, Stefan Haak, Janet Peper-Gabriel, Vanessa Neiens and Christine Rothe

5. Overcoming the limitations of cytokines to improve cancer therapy
Claudia Augusta Di Trani, Assunta Cirella, Leire Arrizabalaga, Myriam Fernandez-Sendin, Angela Bella, Fernando Aranda, Ignacio Melero and Pedro Berraondo

6. Emerging applications of nanobodies in cancer therapy
Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W.M. De Groof, Yannick De Vlaeminck, Ahmet Krasniqi, Kim De Veirman, Cleo Goyvaerts, Matthias D’Huyvetter, Sophie Hernot, Nick Devoogdt and Karine Breckpot

Product details

  • Edition: 1
  • Latest edition
  • Volume: 369
  • Published: June 29, 2022
  • Language: English

About the editors

FA

Fernando Aranda Vega

Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.
Affiliations and expertise
Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

PB

Pedro Berraondo

Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.
Affiliations and expertise
CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

LG

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

View book on ScienceDirect

Read New Antibody Formats on ScienceDirect